Replies to post #127332 on Biotech Values

[pcrutch]

Can NVS extend the patent life of Gleevec via this indication(PAH)? I think I saw it expires in 2015.

[genisi]

not good for UTHR

Not necessarily as Gleevec was tested on top of at least 2 medications as an add-on therapy in patients with more advanced disease:

Criteria
Inclusion Criteria:

Current diagnosis of pulmonary arterial hypertension according to the Dana Point 2008 meeting
PVR = 800 dynes.sec.cm-5 despite treatment with 2 or more specific PAH therapies: endothelial receptor antagonists, phosphodiesterase 5 inhibitors, and prostacyclin analogues
WHO functional class II - IV
6 MWD = 150 meters and = 450 meters at screening

http://clinicaltrials.gov/ct2/show/NCT00902174